| First Author | Jain S | Year | 2013 |
| Journal | J Clin Invest | Volume | 123 |
| Issue | 4 | Pages | 1750-62 |
| PubMed ID | 23478411 | Mgi Jnum | J:197536 |
| Mgi Id | MGI:5493347 | Doi | 10.1172/JCI66432 |
| Citation | Jain S, et al. (2013) Chronic activation of a designer G(q)-coupled receptor improves beta cell function. J Clin Invest 123(4):1750-62 |
| abstractText | Type 2 diabetes (T2D) has emerged as a major threat to human health in most parts of the world. Therapeutic strategies aimed at improving pancreatic beta cell function are predicted to prove beneficial for the treatment of T2D. In the present study, we demonstrate that drug-mediated, chronic, and selective activation of beta cell G(q) signaling greatly improve beta cell function and glucose homeostasis in mice. These beneficial metabolic effects were accompanied by the enhanced expression of many genes critical for beta cell function, maintenance, and differentiation. By employing a combination of in vivo and in vitro approaches, we identified a novel beta cell pathway through which receptor-activated G(q) leads to the sequential activation of ERK1/2 and IRS2 signaling, thus triggering a series of events that greatly improve beta cell function. Importantly, we found that chronic stimulation of a designer G(q)-coupled receptor selectively expressed in beta cells prevented both streptozotocin-induced diabetes and the metabolic deficits associated with the consumption of a high-fat diet in mice. Since beta cells are endowed with numerous receptors that mediate their cellular effects via activation of G(q)-type G proteins, our findings provide a rational basis for the development of novel antidiabetic drugs targeting this class of receptors. |
